Table 4 Number of PSA tests, prostate cancer diagnoses and treatments and costs (in kEuro 2008) of a cohort of 100 000 men of all ages in the period 2008–2033
From: Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
55–70, 1 year | 55–70, 2 year | 55–75, 4 year | |
|---|---|---|---|
PSA tests | 453 740 | 243 387 | 163 545 |
Biopsies | 24 488 | 23 759 | 29 954 |
Cancers detected | 5850 | 5709 | 6981 |
Active surveillance | 1714 | 1614 | 1942 |
Radical prostatectomy | 1792 | 1779 | 2214 |
Radiation therapy | 2099 | 2065 | 2608 |
Palliative therapy | 245 | 251 | 217 |
Palliative therapy after primary treatment | 218 | 246 | 277 |
Costs screening (kEuro) | 10 890 (14%) | 5841 (8%) | 3925 (5%) |
Costs biopsies and treatment | |||
Clinical | 13 032 (17%) | 13 695 (19%) | 9889 (12%) |
Relevant | 22 758 (30%) | 22 476 (32%) | 27 412 (33%) |
Overdetected | 29 446 (39%) | 28 524 (40%) | 42 165 (51%) |
Total costs (kEuro) | 76 126 | 70 536 | 83 391 |
